文献速递食管胃疾病与幽门螺杆菌胃肠动力与功能性疾病

GLP-1受体激动剂与消化性溃疡病风险降低相关:全国性队列研究

Glucagon-like Peptide-1 Receptor Agonists Are Associated With a Lower Risk of Peptic Ulcer Disease: A Nationwide Cohort Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-08-25

基于「All of Us」数据库的全国性回顾性队列纳入66,102例2型糖尿病成人,调整混杂后GLP-1受体激动剂使用与消化性溃疡病诊断几率显著降低相关(aOR 0.56)。亚组分析中,作为二线治疗换用GLP-1受体激动剂较换用胰岛素与溃疡风险显著降低相关(aHR 0.44)。

要点

  • GLP-1受体激动剂使用与消化性溃疡病诊断几率降低相关(aOR 0.56)。
  • 二线换用GLP-1受体激动剂较胰岛素与溃疡风险降低相关(aHR 0.44)。
  • 活动性使用NSAIDs(HR 2.39)和类固醇(HR 1.84)与溃疡风险增加相关。

核心结论

  • 在2型糖尿病成人中,GLP-1受体激动剂使用与消化性溃疡病诊断几率降低相关。
  • 作为二线治疗换用GLP-1受体激动剂较换用胰岛素与消化性溃疡病风险降低相关。

研究设计与样本

  • 全国性回顾性研究,使用美国国立卫生研究院「All of Us」数据库。
  • 主要分析纳入66,102例2型糖尿病成人。
  • 亚组分析纳入3,313例新起始GLP-1受体激动剂(1,270例)或胰岛素(2,043例)作为二线治疗的患者。
  • 主要结局为时间依赖性使用GLP-1受体激动剂后消化性溃疡病诊断的比值比,调整胰岛素、NSAIDs、类固醇、质子泵抑制剂等混杂因素。
  • 亚组分析采用加权时变Cox比例风险模型,并考虑死亡和胃切除术的竞争风险。

主要发现

  • 调整混杂后,GLP-1受体激动剂与消化性溃疡病诊断几率显著降低相关(aOR 0.56;95%CI 0.45-0.71;P < .001)。
  • 亚组中,二线换用GLP-1受体激动剂较换用胰岛素与消化性溃疡病风险显著降低相关(aHR 0.44;95%CI 0.30-0.63;P < .001)。
  • 活动性使用NSAIDs(HR 2.39)和类固醇(HR 1.84)与消化性溃疡病可能性增加相关。

临床怎么用

  • 对于2型糖尿病患者,GLP-1受体激动剂的使用可能与消化性溃疡病风险降低相关。
  • 二线治疗选择GLP-1受体激动剂而非胰岛素时,可能与更低的消化性溃疡病风险相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are prescribed for type 2 diabetes mellitus (T2DM) to improve glycemic control and lower cardiovascular risk. Although the impact of GLP-1RAs on gastrointestinal motility has been characterized, their association with mucosal damage, such as in peptic ulcer disease (PUD), has received little attention. METHODS: We conducted a nationwide retrospective study of adults with T2DM using the "All of Us" National Institutes of Health database, including a sub-group analysis of adults who were newly initiated on GLP-1RAs or insulin as second-line therapy. Our primary outcome was the odds of PUD diagnosis after time-dependent use of GLP-1RAs, adjusting for use of insulin, nonsteroidal anti-inflammatory drugs, steroids, and proton pump inhibitors and other confounders. In a subgroup analysis, we used a weighted, time-varying Cox proportional hazards model, while accounting for the competing risks of death and gastrectomy. RESULTS: A total of 66,102 participants with T2DM were identified and included in our primary analysis. After adjusting for possible confounders, GLP-1RAs were associated with significantly lower odds of PUD diagnosis (adjusted odds ratio 0.56; 95% confidence interval, 0.45-0.71; P < .001). Our subgroup included a total of 3313 patients (1270 new GLP-1RA users; 2043 new insulin users). In this analysis, switching to a GLP-1RA as second-line therapy was associated with a significantly lower hazard of PUD compared with switching to insulin (adjusted hazard ratio [HR], 0.44; 95% confidence interval, 0.30-0.63; P < .001). The model confirmed that active use of nonsteroidal anti-inflammatory drugs (HR, 2.39) and steroids (HR, 1.84) were also associated with increased likelihood of PUD. CONCLUSIONS: In this nationwide cohort study of patients with T2DM, GLP-1RA use was associated with 44% lower odds of PUD. In our propensity score-matched subgroup, switching to GLP-1RA as second-line therapy was associated with a 56% lower hazard of PUD vs insulin. These findings indicate an association between GLP-1RA use and reduced risk of PUD.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Seika P, Chang J, Hong SM, et al. Glucagon-like Peptide-1 Receptor Agonists Are Associated With a Lower Risk of Peptic Ulcer Disease: A Nationwide Cohort Study. Clin Gastroenterol Hepatol. 2025. PMID: 40865627. doi:10.1016/j.cgh.2025.08.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。